Comparison of ready-to-use and vial infusions of zoledronic acid
Manjinder Bains Brand manager, Oncology, Novartis
Martin Rees-Milton Principal pharmacist, Velindre Cancer Centre, Cardiff
Meryl Moremon Ward manager, Velindre Cancer Centre, Cardiff
Inderjit Mandair Medical director, UK, A Menarini Pharma
Manjinder Bains and colleagues present the results of a study to assess whether the use of pre-diluted solutions to treat patients with bone metastases reduces time from preparation to completion of therapy in day unit and mobile clinic settings
Aim To compare the ready-to-use and vial formulations of zoledronic acid in terms of the time taken to prepare, check and administer the infusion in nurse-led outpatient and mobile clinic settings.
Method A prospective study of adult patients receiving zoledronic acid for the treatment of bone metastases was undertaken. Timings were captured for vital steps in the administration process.
Results Assessments of 111 infusions were made. Eight infusions were excluded because patients had received concurrent chemotherapy, leaving 56 infusions in the vials arm and 47 in the ready-to-use arm. The median total time to prepare and check a dose was significantly reduced in the ready-to-use arm compared with the vials arm in the mobile unit (00:00:28 v 00:04:47; P<0.0001) and day unit (00:01:33 v 00:03:05; P<0.0001) settings. In the mobile unit setting, this translated to significant savings in total preparation and infusion (00:25:11 v 00:32:50; P=0.0015). However, in the day unit setting, no difference in the arms was apparent (00:36:01 v 00:35:46; P=0.6169).
Conclusion The ready-to-use formulation of zoledronic acid appears to be a viable alternative to the existing vials formulation and has the potential to help practical administration of the therapy.
Cancer Nursing Practice.
12, 5, 29-35.
doi: 10.7748/cnp2013.06.12.5.29.e947
Correspondence
manjinder.bains@novartis.com
Peer review
This article has been subject to double blind peer review
Conflict of interest
Novartis provided funding for the study, which included the employment of a medical writer and data analyst. Manjinder Bains is employed by Novartis, as was Inderjit Mandair at the time of writing
Received: 10 January 2013
Accepted: 07 March 2013
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more